216 Treatment of advanced ovarian carcinoma with tamoxifen. a phase II trial

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines

“…Results from clinical trials have yielded conflicting data as to the potential role of anti-oestrogen therapy for the treatment of ovarian cancer (Schwartz et al, 1982;Pagel et al, 1983;Hamerlynck et al, 1985;Campbell et al, 1984;Slevin et al, 1986;Shirey et al, 1984;Landoni et al, 1983). To assess further the role of such therapy, we have examined the effects of oestrogen and tamoxifen on the growth of ER + ve and ER -ve oestrogen carcinoma cell The influence of 17 P-oestradiol on the growth of an ER + ve cell line, PE04, was examined to determine if there was evidence of oestrogen-sensitivity.…”

“…As measured by a dextran-coated charcoal adsorption assay, cell lines PEOI, PEO4 (Schwartz et al, 1982;Pagel et al, 1983;Hamerlynck et al, 1985;Campbell et al, 1984), although others have failed to demonstrate such benefits Slevin et al, 1986;Shirey et al, 1984;Landoni et al, 1983).We have recently derived and characterized a series of human ovarian carcinoma cell lines (Langdon et al, 1988). In the present study, we measured the levels of ER in these lines and examined the effects of 17 P-oestradiol and the anti-oestrogen tamoxifen on the growth of two of these lines -the ER +ve line PE04 and the ER -ve line, PE014.…”

“…As measured by a dextran-coated charcoal adsorption assay, cell lines PEOI, PEO4 (Schwartz et al, 1982;Pagel et al, 1983;Hamerlynck et al, 1985;Campbell et al, 1984), although others have failed to demonstrate such benefits Slevin et al, 1986;Shirey et al, 1984;Landoni et al, 1983).…”

“…The presence of oestrogen receptors (ER) in the majority of ovarian tumours (Pollow et al, 1983;Jones et al, 1983;Ford et al, 1983;Slotman & Rao, 1988) (Schwartz et al, 1982;Pagel et al, 1983;Hamerlynck et al, 1985;Campbell et al, 1984), although others have failed to demonstrate such benefits Slevin et al, 1986;Shirey et al, 1984;Landoni et al, 1983).…”

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule

“…Objective responses to anti-oestrogen therapy have been observed in advanced ovarian cancer by a number of workers (Myers et al, 1981;Schwartz et al, 1982;Pagel et al, 1983;Campbell et al, 1984;Hamerlynck et al, 1985). However, the true value of this form of treatment remains unclear, since several studies have shown apparently negligible activity (Rowland et al, 1985;Shirey et al, 1985;Slevin et al, 1986).…”